Drug Shortage Report for APO-SITAGLIPTIN/METFORMIN XR
Report ID | 185982 |
Drug Identification Number | 02506289 |
Brand name | APO-SITAGLIPTIN/METFORMIN XR |
Common or Proper name | SITAGLIPTAN PHOSPHATE/METFORMIN |
Company Name | APOTEX INC |
Market Status | MARKETED |
Active Ingredient(s) | METFORMIN HYDROCHLORIDE SITAGLIPTIN |
Strength(s) | 1000MG 50MG |
Dosage form(s) | TABLET (EXTENDED-RELEASE) |
Route of administration | ORAL |
Packaging size | 500 BTL |
ATC code | A10BD |
ATC description | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2023-03-02 |
Estimated end date | 2024-01-31 |
Actual end date | 2024-02-01 |
Shortage status | Resolved |
Updated date | 2024-02-02 |
Company comments | Product on allocation due to increased demand |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 150 SIGNET DRIVE TORONTO, ONTARIO CANADA M9L 1T9 |
Company contact information | Apotex Customer Service - 1-877-427-6839 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.